Raloxifene

Raloxifene Impurities

Raloxifene impurities include process-related compounds, synthetic intermediates, and degradation products that may arise during synthesis, formulation, or storage. As a selective estrogen receptor modulator (SERM) used in the prevention and treatment of osteoporosis and reduction of breast cancer risk in postmenopausal women, impurity profiling is essential to ensure product safety, therapeutic efficacy, and regulatory compliance. All impurity compounds are structurally characterized and qualified under ICH guidelines for toxicological evaluation and analytical validation.

Raloxifene EP Impurities

Pharmacopeial and non-pharmacopeial Raloxifene impurity compounds are available in compliance with European Pharmacopoeia (EP) specifications. These standards support analytical method development, impurity profiling, and stability testing. EP traceable materials are supplied with validated analytical data including purity, structural confirmation, and spectral characterization.

Raloxifene Related Compounds

Structurally related compounds and synthetic analogs associated with Raloxifene are included for use in impurity identification, toxicological qualification, and regulatory submission. These materials are thoroughly characterized and conform to international standards. Related compounds are used in forced degradation studies, genotoxicity assessments, and impurity threshold evaluations.

Raloxifene Impurity Reference Standards

Raloxifene impurity reference standards are provided with validated analytical data including purity, NMR, and MS. These standards are used in pharmaceutical research, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.